Our Next Show: Preventing Myeloma Bone Damage Using a New Compound with Dr. Irene Ghobrial, MD, PhD, Dana Farber Cancer Institute
Call In by Phone to Listen Live: (347) 637-2631 orBone damage is one of the most painful and deadly effects of multiple myeloma. Learn about a new compound that is in early clinical trials to make the bone marrow microenvironment unfriendly to the myeloma and prevent it from settling into the bones. Dr. Irene Ghobrial will describe her work on a new compound called SDF-1 (stromal cell-derived factor-1) which acts as a protein magnet, attracting certain cells to new locations within the bone marrow. This compound is now in early clinical trials and is showing that it can stop progression of the disease in the bones.
Dr. Irene M. Ghobrial, MD, PhD is an Associate Professor of Medicine at Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA. She is a physician Scientist who specializes in the field of Multiple Myeloma and Waldenstrom Macroglobulinemia, specifically in the precursor conditions of MGUS and Smoldering disease. She particularly focuses on the role of the malignant bone marrow niche in disease progression from early precursor conditions like MGUS/smoldering MM to overt MM. She uses MM as a model of bone metastasis and dissemination. Dr. Ghobrial and her lab attempt to examine how MM can use a process of cell dissemination that is similar to cell trafficking of hematopoietic stem cell (HSCs) and cell metastasis in solid epithelial carcinomas. These studies can guide our understanding of the biological changes that occur during progression in MM. In addition, her laboratory research data has been rapidly translated to innovative investigator-initiated clinical trials. They have conducted over 10 phase I and II clinical trials. Their studies on MM cell trafficking have been translated to the first chemosensitization trials in patients with Multiple Myeloma. In addition, she is the co-leader of the first consortium of clinical trials for blood cancers in collaboration with the Leukemia and Lymphoma Society to form the Blood Cancer Research Partnership (BCRP), a consortium for innovative clinical trials of 11 community oncology sites coordinated by DFCI. Moreover, She initiated a new clinic for Prevention of Progression in Blood Cancers where patients with precursor conditions such as MGUS, early MDS and early CLL will be monitored propsectively for clonal evolution during disease progression. Clinical trials and research efforts are coordinated for patients seen in this clinic to develop therapeutic agents that can prevent/delay disease progression in these early malignant conditions.